Two doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 6, Issue 9, 2007, Pages 634-640

  Moreno Solórzano, Isabel ^a,d   Ibeas Rollan, Rafael ^a   Monzó Planella, Mariano ^b   Moreno Solórzano, José ^c   Martínez Ródenas, Francisco ^c   Pou Sanchis, Edmon ^c   Hernández Borlan, Raquel ^c   Navarro Vigo, Marta ^a   Ortigosa Rodríguez, Silvia ^a   Gel Moreno, Bernat ^b  

^a Hospital Municipal de Badalona   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Hospital Municipal de Badalona   (Spain)

^d Hospital Municipal de Badalona   (Spain)

Author keywords

Chemotherapy; Neurotoxicity; Survival; Time to progression

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DEXAMETHASONE; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; RALTITREXED; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CARDIOTOXICITY; CLINICAL ARTICLE; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DYSESTHESIA; FEMALE; FUNCTIONAL DISEASE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; LIVER TOXICITY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 35348908108     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2007.n.031     Document Type: Article

References (31)

1. O'Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 1989; 63:1026-1030.
2. Grothey A, Schmoll HJ. New chemotherapy approaches in colorectal cancer. Curr Opin Oncol 2001; 13:275-286.
3. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
4. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5 fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002; 21:129a (Abstract #512).
5. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomised trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastasic colorectal cancer. J Clin Oncol 2000; 18:136-147.
6. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastasic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
7. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastasic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
8. Cunningham D, Humblet Y, Sienas S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT11) in patients with epidermal growth factor receptor (EGFR)- positive, irinotecan refractory metastasic colorectal cancer (MCRC). N Engl J Med 2003; 22:252.
9. Hurwitz H, Fehrenbacher L, Hainsworth J, et al. Bevacizumab in combination with 5-fluorouracil and leucovorin: a promising regimen for first-line metastasic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
10. Miwa M, Ura M, Nishida M, et al. design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281.
11. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine versus intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004; 90:1190-1197.
12. Diaz-Rubio E, Evans TR, Tabernero J, et al. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol 2002; 13:558-565.
13. Grothey A, Jordan K, Kellner O, et al. Capecitabine/irinotecan (CapIri) and capecitabine/oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy: results of a randomised phase II study. Proc Am Soc Clin Oncol 2004; 23:254 (Abstract #3534).
14. Patt YZ, Lin E, Liebman J, et al. Capecitabine plus irinotecan: a highly active first-line treatment for metastatic colorectal cancer (MCRC). Presented at: 2004 American Society of Clinical Oncology Gastrointestinal Symposium; January 22-24, 2004; San Francisco, CA. Abstract #228.
15. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22:2084-2091.
16. Cascinu S, Graziano F, Ferraù F, et al. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol 2002; 13:716-720.
17. Therasse P, Abuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
18. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
19. Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma. Final results of the Southern Italy Cooperative Oncology Group trial 0108. Cancer 2005; 104:282-289.
20. Sastre J, Massuti B, Tabernero M, et al. Preliminary results of a randomised phase III trial of the TTD Group comparing capecitabine and oxaliplatin (CapeOx) vs oxaliplatin and 5-fluorouracil in continuous infusion (5-FU CI) as first line treatment in advanced or metastatic colorectal cancer (CRC). J Clin Oncol 2005; 23(16 suppl):252s (Abstract #3524).
21. Arkenau T, Schmoll H, Kubicka S, et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): results of the safety and efficacy analysis. J Clin Oncol 2005; 23(16 suppl):247s (Abstract #3507).
22. Golberg RM, Sargent DJ, Morton RG, et al. A randomised controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
23. Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21:1307-1312.
24. Borner MM, Dietrich D, Stupp R, et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 20:1759-1766.
25. Zeuli M, Nardoni C, Pino MS, et al. Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 2003; 14:1378-1382.
26. Ribelles N, Sánchez A, López Siles J, et al. Pharmacogenetic study in patients (pts) with metastatic breast (BC) and colorectal (CRC) treated with capecitabine (C). J Clin Oncol 2005; 23(16 suppl):136s (Abstract #2005).
27. Vila JM, Moreno I, Monzo M, et al. XPD, XPA, ERCC1 and XPG/ERCC5 single nucleotide polymorphisms (SNPs) in oxaliplatin-treated colorectal cancer (CRC). Proc Am Soc Clin Oncol 2004; 23:289 (Abstract #3677).
28. Ibeas R, Monzo M, Moreno I, et al. Cytidine deaminase (CD) and dihydropyrimidine dehydrogenase (DPD) single nucleotide polymorphism (SNPs) in capecitabine-treated colorectal cancer (CRC). Proc Am Soc Clin Oncol 2004; 23:285 (Abstract #3662).
29. Martinez-Balibrea E, Manzano JL, Catot S, et al. Predictive value of single nucleotide polymorphisms (SNPs) in DNA repair genes in non-selected advanced colorectal cancer (CRC) patients (p) treated with oxaliplatin (OXA) plus 5-fluorouracil (5-FU) first-line chemotherapy (CT). Proc Am Soc Clin Oncol 2004; 23:290 (Abstract #3680).
30. Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007; 25:102-109.
31. Cassidy J, Clarke S, Diaz-Rubio E, et al. First efficacy and safety results from XELOX-I/NO 16966, a randomized 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Ann Oncol 2006; 17(9 suppl): (Abstract #LBA3).